Literature DB >> 8192468

Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.

G A Pankuch1, M R Jacobs, P C Appelbaum.   

Abstract

The susceptibilities of 123 clinically isolated strains of Xanthomonas maltophilia to six fluoroquinolones (clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin) were examined by microdilution MIC methodology. Clinafloxacin and PD 131628 were the most active compounds tested (MICs for 50% of the strains tested [MIC50s] of 0.5 and 1.0 microgram/ml and MIC90s of 2.0 and 4.0 micrograms/ml, respectively). PD 138312, PD 140248, ciprofloxacin, and ofloxacin were less active, with MIC50s ranging from 4.0 to 8.0 micrograms/ml and MIC90s of 16.0 micrograms/ml for all four compounds. Only clinafloxacin and PD 131628 were active against ciprofloxacin-resistant strains, with MIC50s of 0.5 and 1.0 microgram/ml and MIC90s of 2.0 and 4.0 micrograms/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8192468      PMCID: PMC284459          DOI: 10.1128/AAC.38.2.369

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

Authors:  P C Fuchs; A L Barry; M A Pfaller; S D Allen; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer.

Authors:  N Khardori; L Elting; E Wong; B Schable; G P Bodey
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors:  A W Chow; J Wong; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

4.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro.

Authors:  M Lecso-Bornet; J Pierre; D Sarkis-Karam; S Lubera; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

6.  In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391.

Authors:  M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; C L Heifetz
Journal:  Diagn Microbiol Infect Dis       Date:  1991 May-Jun       Impact factor: 2.803

7.  Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents.

Authors:  A Louie; A L Baltch; W J Ritz; R P Smith
Journal:  J Antimicrob Chemother       Date:  1991-06       Impact factor: 5.790

8.  Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature.

Authors:  J J Zuravleff; V L Yu
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

9.  Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks.

Authors:  A L Barry; R J Fass; J P Anhalt; H C Neu; C Thornsberry; R C Tilton; B G Painter; J A Washington
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

10.  Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics.

Authors:  G Bonfiglio; D M Livermore
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

View more
  11 in total

1.  Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.

Authors:  S Valdezate; A Vindel; E Loza; F Baquero; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Pseudo-, Xantho-, and now Stenotrophomonas maltophilia: New kid on the block.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1996-03

3.  In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 6.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

7.  Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model.

Authors:  M W Garrison; D E Anderson; D M Campbell; K C Carroll; C L Malone; J D Anderson; R J Hollis; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 8.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

9.  Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.

Authors:  J A García-Rodríguez; J E García Sánchez; I Trujillano; E García Sánchez; M I García García; M J Fresnadillo
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

10.  In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  C D Poulos; S O Matsumura; B M Willey; D E Low; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.